KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) EBT Margin (2016 - 2025)

Historic EBT Margin for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to 6.37%.

  • Teva Pharmaceutical Industries' EBT Margin rose 122100.0% to 6.37% in Q4 2025 from the same period last year, while for Dec 2025 it was 8.36%, marking a year-over-year increase of 104800.0%. This contributed to the annual value of 7.09% for FY2025, which is 148500.0% up from last year.
  • As of Q4 2025, Teva Pharmaceutical Industries' EBT Margin stood at 6.37%, which was up 122100.0% from 14.42% recorded in Q3 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' EBT Margin peaked at 14.42% during Q3 2025, and registered a low of 39.38% during Q4 2023.
  • Moreover, its 5-year median value for EBT Margin was 1.3% (2021), whereas its average is 5.45%.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' EBT Margin soared by 1219200bps in 2021, and later crashed by -389900bps in 2022.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' EBT Margin stood at 4.27% in 2021, then tumbled by -615bps to 30.51% in 2022, then decreased by -29bps to 39.38% in 2023, then surged by 85bps to 5.84% in 2024, then soared by 209bps to 6.37% in 2025.
  • Its last three reported values are 6.37% in Q4 2025, 14.42% for Q3 2025, and 4.86% during Q2 2025.